Kura Oncology (NASDAQ:KURA) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Thursday morning, Benzinga reports. HC Wainwright currently has a $32.00 target price on the stock.

A number of other research firms also recently issued reports on KURA. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday. They issued a “buy” rating and a $27.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Trading Down 1.5 %

Shares of Kura Oncology stock opened at $17.51 on Thursday. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -7.85 and a beta of 0.84. Kura Oncology has a 52-week low of $7.52 and a 52-week high of $24.17. The company’s 50-day simple moving average is $19.34 and its 200-day simple moving average is $20.09.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the previous year, the company earned ($0.53) EPS. The company’s quarterly revenue was up .0% on a year-over-year basis. As a group, equities research analysts anticipate that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. Vanguard Group Inc. boosted its holdings in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the period. Armistice Capital LLC grew its holdings in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Artal Group S.A. increased its stake in Kura Oncology by 8.6% during the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after buying an additional 151,828 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.